On November 16, 2022, “JAMA Network Open” (IF: 13.35) published the original article by the team of Professors Lian Wei and Xing Bing from Peking Union Medical College Hospital (PUMCH). In this randomized trial (RCT), authors found that no hydrocortisone application during the perioperative period was safe for pituitary adenoma patients with normal hypothalamic-pituitary-adrenal axis (HPA) axis. The study also suggested that hormone monitoring should be strengthened during the perioperative period for patients with preoperative serum cortisol level below 9.25 μg/dL at 8 a.m.

Globally, approximately 270,000 patients are diagnosed with pituitary adenoma and undergo surgery each year. This study is expected to change the guidelines for the management of pituitary adenoma. Further popularization of the research results will also reduce the unnecessary use of hydrocortisone for the benefit of patients worldwide.

The primary, secondary and other outcomes of the trial

Correspondent: Guo Xiaopeng

Reporter: Gan Dingzhu

Picture courtesy: Guo Xiaopeng

Translator: Liu Haiyan

Editor: Wang Yu and Wang Yao